RA0304

antibody from Oursmab

Targeting: ICOSLG B7-H2, B7h, B7H2, B7RP-1, B7RP1, CD275, GL50, ICOS-L, ICOSL, KIAA0653

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0304

Provider

Oursmab

Product name

Prezalumab (Biosimilar Reference Antibody) (ICOSLG)

Antibody type

Monoclonal

Description

Prezalumab (also known as AMG 557 or the proposed international nonproprietary name Praelumab) is a humanized IgG2 monoclonal antibody developed for the treatment of autoimmune and inflammatory diseases. It possesses a unique dual-targeting mechanism, designed to simultaneously bind to and neutralize two key immunomodulatory ligands: Inducible T-cell Co-stimulator Ligand (ICOSL) and B-cell Activating Factor (BAFF, also known as BLyS). By inhibiting both ICOSL and BAFF, prezalumab aims to comprehensively suppress pathogenic immune activation. It blocks the ICOS-ICOSL co-stimulatory pathway crucial for T-cell and antigen-presenting cell interactions, and concurrently inhibits the BAFF-mediated survival and differentiation of autoreactive B cells. This combined action targets multiple drivers of autoimmunity.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.